| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| John D Outen, M Haroon Burhanullah, Ryan Vandrey, Halima Amjad, David G Harper, Regan E Patrick, Rose L May, Marc E Agronin, Brent P Forester, Paul B Rosenber. Cannabinoids for Agitation in Alzheimer's Disease. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. vol 29. issue 12. 2021-11-29. PMID:33573996. |
cannabinoids for agitation in alzheimer's disease. |
2021-11-29 |
2023-08-13 |
Not clear |
| Joseph S Govea. Commentary on "Cannabinoids for Agitation in Alzheimer's Disease". The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. vol 29. issue 12. 2021-11-29. PMID:33839012. |
commentary on "cannabinoids for agitation in alzheimer's disease". |
2021-11-29 |
2023-08-13 |
Not clear |
| Deepthi Rapaka, Veera Raghavulu Bitra, Siva Reddy Challa, Paul C Adiukw. Potentiation of microglial endocannabinoid signaling alleviates neuroinflammation in Alzheimer's disease. Neuropeptides. vol 90. 2021-11-22. PMID:34508923. |
potentiation of microglial endocannabinoid signaling alleviates neuroinflammation in alzheimer's disease. |
2021-11-22 |
2023-08-13 |
Not clear |
| Deepthi Rapaka, Veera Raghavulu Bitra, Siva Reddy Challa, Paul C Adiukw. Potentiation of microglial endocannabinoid signaling alleviates neuroinflammation in Alzheimer's disease. Neuropeptides. vol 90. 2021-11-22. PMID:34508923. |
the exploitation of therapeutic actions of endocannabinoid system has newly emerged in the field of alzheimer's disease. |
2021-11-22 |
2023-08-13 |
Not clear |
| Jaedong Lee, Jeehyun Kwa. Activation of PLCβ1 enhances endocannabinoid mobilization to restore hippocampal spike-timing-dependent potentiation and contextual fear memory impaired by Alzheimer's amyloidosis. Alzheimer's research & therapy. vol 13. issue 1. 2021-10-28. PMID:34625112. |
activation of plcβ1 enhances endocannabinoid mobilization to restore hippocampal spike-timing-dependent potentiation and contextual fear memory impaired by alzheimer's amyloidosis. |
2021-10-28 |
2023-08-13 |
Not clear |
| Alex J Berry, Olga Zubko, Suzanne J Reeves, Robert J Howar. Endocannabinoid system alterations in Alzheimer's disease: A systematic review of human studies. Brain research. vol 1749. 2021-10-27. PMID:32980333. |
endocannabinoid system alterations in alzheimer's disease: a systematic review of human studies. |
2021-10-27 |
2023-08-13 |
human |
| Alex J Berry, Olga Zubko, Suzanne J Reeves, Robert J Howar. Endocannabinoid system alterations in Alzheimer's disease: A systematic review of human studies. Brain research. vol 1749. 2021-10-27. PMID:32980333. |
studies investigating alterations of the endocannabinoid system (ecs) in alzheimer's disease (ad) in humans have reported inconsistent findings so far. |
2021-10-27 |
2023-08-13 |
human |
| Ana Gabriela Hounie, Marco Agassiz Almeida Vasque. Neurological Improvement with Medical Cannabis in a Progressive Supranuclear Palsy Patient: A Case Report. Medical cannabis and cannabinoids. vol 2. issue 2. 2021-10-23. PMID:34676336. |
progressive supranuclear palsy (psp) is a severe, debilitating, and often fatal disease resembling other neurodegenerative disorders, namely alzheimer's (ad) and parkinson's (pd) diseases, which have been successfully treated with cannabinoids. |
2021-10-23 |
2023-08-13 |
Not clear |
| Tiziana Bisogno, Anna Lauritano, Fabiana Piscitell. The Endocannabinoid System: A Bridge between Alzheimer's Disease and Gut Microbiota. Life (Basel, Switzerland). vol 11. issue 9. 2021-10-01. PMID:34575083. |
the endocannabinoid system: a bridge between alzheimer's disease and gut microbiota. |
2021-10-01 |
2023-08-13 |
human |
| Viviana Soto-Mercado, Miguel Mendivil-Perez, Marlene Jimenez-Del-Rio, Carlos Velez-Pard. Multi-Target Effects of the Cannabinoid CP55940 on Familial Alzheimer's Disease PSEN1 E280A Cholinergic-Like Neurons: Role of CB1 Receptor. Journal of Alzheimer's disease : JAD. vol 82. issue s1. 2021-09-23. PMID:33252082. |
multi-target effects of the cannabinoid cp55940 on familial alzheimer's disease psen1 e280a cholinergic-like neurons: role of cb1 receptor. |
2021-09-23 |
2023-08-13 |
Not clear |
| Abraham Nudelma. Dimeric Drugs. Current medicinal chemistry. 2021-08-10. PMID:34375175. |
other symmetrical-dimeric drugs include antidiabetics, antidepressants, analgesics, anti-inflammatories, drugs for the treatment of alzheimer's disease, anticholesterolemics, estrogenics, antioxidants, enzyme inhibitors, anti-parkisonians, laxatives, antiallergy compounds, cannabinoids, etc. |
2021-08-10 |
2023-08-13 |
Not clear |
| Serena Montanari, Marco Allarà, Laura Scalvini, Magdalena Kostrzewa, Federica Belluti, Silvia Gobbi, Marina Naldi, Silvia Rivara, Manuela Bartolini, Alessia Ligresti, Alessandra Bisi, Angela Ramp. New Coumarin Derivatives as Cholinergic and Cannabinoid System Modulators. Molecules (Basel, Switzerland). vol 26. issue 11. 2021-07-22. PMID:34071439. |
in the last years, the connection between the endocannabinoid system (ecs) and neuroprotection has been discovered, and evidence indicates that ecs signaling is involved in the regulation of cognitive processes and in the pathophysiology of alzheimer's disease (ad). |
2021-07-22 |
2023-08-13 |
Not clear |
| Sebastián García, Virna Margarita Martín Giménez, Feres José Mocayar Marón, Russel J Reiter, Walter Manuch. Melatonin and cannabinoids: mitochondrial-targeted molecules that may reduce inflammaging in neurodegenerative diseases. Histology and histopathology. vol 35. issue 8. 2021-07-09. PMID:32154907. |
of particular interest, melatonin, cannabinoids, and the receptors of both molecules which are closely related, exert beneficial effects on the neuroinflammatory processes that precede the onset of neurodegenerative pathologies such as parkinson's and alzheimer's diseases. |
2021-07-09 |
2023-08-13 |
Not clear |
| Giulia Abate, Daniela Uberti, Simone Tambar. Potential and Limits of Cannabinoids in Alzheimer's Disease Therapy. Biology. vol 10. issue 6. 2021-07-05. PMID:34204237. |
potential and limits of cannabinoids in alzheimer's disease therapy. |
2021-07-05 |
2023-08-13 |
Not clear |
| R Cooray, V Gupta, C Suphiogl. Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson's and Alzheimer's Diseases: a Review. Molecular neurobiology. vol 57. issue 11. 2021-06-29. PMID:32813239. |
current aspects of the endocannabinoid system and targeted thc and cbd phytocannabinoids as potential therapeutics for parkinson's and alzheimer's diseases: a review. |
2021-06-29 |
2023-08-13 |
human |
| Kadja Luana Chagas Monteiro, Marcone Gomes Dos Santos Alcântara, Thiago Mendonça de Aquino, Edeildo Ferreira da Silva-Júnio. Cannabinoid pharmacology and its therapeutic uses in Alzheimer's disease. Neural regeneration research. vol 16. issue 5. 2021-06-23. PMID:33229747. |
cannabinoid pharmacology and its therapeutic uses in alzheimer's disease. |
2021-06-23 |
2023-08-13 |
Not clear |
| José María Sánchez Montero, Angel Agis-Torres, David Solano, Monica Söllhuber, María Fernandez, Wilma Villaro, María Gómez-Cañas, Moisés García-Arencibia, Javier Fernández-Ruiz, Javier Egea, María Isabel Martín, Rocío Giró. Analogues of cannabinoids as multitarget drugs in the treatment of Alzheimer's disease. European journal of pharmacology. vol 895. 2021-05-19. PMID:33460612. |
analogues of cannabinoids as multitarget drugs in the treatment of alzheimer's disease. |
2021-05-19 |
2023-08-13 |
Not clear |
| Horia Paunescu, Lorena Dima, Isabel Ghita, Laurenţiu Coman, Petru Iulian Ifteni, Ion Fulga, Oana Andreia Coma. A Systematic Review of Clinical Studies on the Effect of Psychoactive Cannabinoids in Psychiatric Conditions in Alzheimer Dementia. American journal of therapeutics. vol 27. issue 3. 2021-03-01. PMID:32118591. |
a systematic review of clinical studies on the effect of psychoactive cannabinoids in psychiatric conditions in alzheimer dementia. |
2021-03-01 |
2023-08-13 |
Not clear |
| Horia Paunescu, Lorena Dima, Isabel Ghita, Laurenţiu Coman, Petru Iulian Ifteni, Ion Fulga, Oana Andreia Coma. A Systematic Review of Clinical Studies on the Effect of Psychoactive Cannabinoids in Psychiatric Conditions in Alzheimer Dementia. American journal of therapeutics. vol 27. issue 3. 2021-03-01. PMID:32118591. |
the systematic reviews and meta-analyses performed until now did not provide the adequate picture of actual knowledge in the field of neuropsychiatric symptoms treatment using psychotropic cannabinoids in patients with alzheimer disease (ad). |
2021-03-01 |
2023-08-13 |
Not clear |
| Leonardo Brunetti, Antonio Carrieri, Luca Piemontese, Paolo Tortorella, Fulvio Loiodice, Antonio Laghezz. Beyond the Canonical Endocannabinoid System. A Screening of PPAR Ligands as FAAH Inhibitors. International journal of molecular sciences. vol 21. issue 19. 2021-02-25. PMID:32987725. |
an increasing body of literature describing the interactions between the endocannabinoid system and ppars has slowly but surely been accumulating over the past decade, and a multitarget approach involving these receptors and endocannabinoid degrading enzyme faah has been proposed for the treatment of inflammatory states, cancer, and alzheimer's disease. |
2021-02-25 |
2023-08-13 |
Not clear |